# Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions

> **NCT05635071** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 90 (estimated)

## Conditions studied

- Uterine Adhesions

## Interventions

- **DRUG:** Nintedanib 100 MG [Ofev]
- **DRUG:** Nintedanib 150 MG [Ofev]

## Key facts

- **NCT ID:** NCT05635071
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-01
- **Primary completion:** 2024-07-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2022-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05635071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05635071, "Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05635071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*